PIVKA-II

DIAGNOSTIC_TEST3 trials

Sponsors

Eastern Hepatobiliary Surgery Hospital, Shanghai Children's Medical Center, Korea University

Conditions

Hepatic HemangioendotheliomaHepatoblastomaHepatocellular CarcinomaLiver CirrhosisSurveillance

Unknown Phase

Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC

CompletedNCT03047603

Eastern Hepatobiliary Surgery HospitalHepatocellular Carcinoma

Start: 2016-05-01End: 2019-03-20Updated: 2024-02-20

PIVKA-II Combined With Alpha-Fetoprotein for Diagnostic and Prognostic Value of Hepatic Tumors in Infants

CompletedNCT03645655

Shanghai Children's Medical CenterHepatic Hemangioendothelioma, Hepatoblastoma

Start: 2018-10-01End: 2021-06-30Updated: 2021-07-23

Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

RecruitingNCT04414956

Korea UniversityHepatocellular Carcinoma, Liver Cirrhosis, Surveillance

Start: 2016-07-01End: 2026-02-28Target: 1418Updated: 2020-06-04

Related Papers

PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study

Hepatology International2024-04-164 citations

A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B

Clinical Chemistry2019-10-31111 citations

A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: A large-scale, multi-center study

Annals of Oncology2018-10-01

Serum ARCHITECT PIVKA-II reference interval in healthy Chinese adults: Sub-analysis from a prospective multicenter study.

2018-02-129 citations

Serum reference interval of ARCHITECT alpha-fetoprotein in healthy Chinese Han adults: Sub-analysis of a prospective multi-center study.

2017-11-102 citations